Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies.
about
TRPV1: on the road to pain reliefFood-Derived Natural Compounds for Pain Relief in Neuropathic PainNon-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgiaTherapeutic strategies for cancer treatment related peripheral neuropathies.Acid-sensitive ion channels and receptorsA sensitive LC-MS/MS method for quantifying capsaicin and dihydrocapsaicin in rabbit plasma and tissue: application to a pharmacokinetic study.TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation.Receptor activity and conformational analysis of 5'-halogenated resiniferatoxin analogs as TRPV1 ligandsThe pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensorVanilloid Receptor 1 Agonists, Capsaicin and Resiniferatoxin, Enhance MHC Class I-restricted Viral Antigen Presentation in Virus-infected Dendritic Cells.Translational pain research: achievements and challengesManagement options for established chemotherapy-induced peripheral neuropathy.Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications.Role of transient receptor potential vanilloid 1 in inflammation and autoimmune diseases.26-Week dermal oncogenicity study evaluating pure trans-capsaicin in Tg.AC hemizygous mice (FBV/N).TRPV1 mediates the uterine capsaicin-induced NMDA NR2B-dependent cross-organ reflex sensitization in anesthetized rats.Capsaicin-induced vasodilatation in human nasal vasculature is mediated by modulation of cyclooxygenase-2 activity and abrogated by sulprostone.Developmental toxicity study of pure trans-capsaicin in rats and rabbits.
P2860
Q24650367-77D22B90-F430-4BEB-8E7D-A8609938CC58Q28068743-0836DCAC-EDDF-4AE6-B67B-437D8657D047Q33559837-88EDE2C7-AA61-4C9E-8B4F-55052B53D57FQ33715079-A9CE264A-2CC4-409B-98C5-5CDC564B1FB1Q34433406-76EFF41B-1BBC-4B91-97B4-2DDE9C6CDBFDQ35178189-0A2F3EE4-3255-422A-B35B-B70D898C488BQ35218081-D726EB1A-B560-454D-885C-E2218CC96032Q36168212-DB934271-D21C-4E89-B360-C4B6F8B0A7EFQ36168257-600A89DD-E260-4A8A-AF6F-3240DC77415DQ37023861-D852D50B-786A-4E10-838A-DC2A4673DA4CQ37212514-4F54F8FF-F748-4CD4-82A0-DCBAC5D4B8B3Q37376539-51226563-03BE-45D6-9D34-697408867944Q38216217-6F048669-223E-4AB9-92A6-199E2ECC8C6FQ38335767-89E3A6E6-323A-4CC9-9855-BEEAE8721E43Q42585825-A9C02600-D0EB-41D8-8D72-4DD8587A33D2Q46173999-2EFBE290-4D7A-49AF-AE21-FA3B2140CA4AQ46480083-D4FC2DC3-E42D-4FAE-878A-DB1BA9FE4CF0Q49064177-F0E15560-9E7D-44E9-911F-21F450656B17Q52017189-3FA569CD-A8B9-4F15-B8D2-CAE881ACDC1A
P2860
Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Recent developments in transie ...... tor 1 agonist-based therapies.
@ast
Recent developments in transie ...... tor 1 agonist-based therapies.
@en
type
label
Recent developments in transie ...... tor 1 agonist-based therapies.
@ast
Recent developments in transie ...... tor 1 agonist-based therapies.
@en
prefLabel
Recent developments in transie ...... tor 1 agonist-based therapies.
@ast
Recent developments in transie ...... tor 1 agonist-based therapies.
@en
P2860
P1476
Recent developments in transie ...... tor 1 agonist-based therapies.
@en
P2093
Keith R Bley
P2860
P304
P356
10.1517/13543784.13.11.1445
P407
P577
2004-11-01T00:00:00Z